Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development

被引：2
|
作者：
Jin, Yujin
Heo, Kyung-Sun [1 ]
机构：
[1] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
来源：
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY | 2023年 / 27卷 / 04期
基金：
新加坡国家研究基金会;
关键词：
Drug targeting; Hepatitis; Metabolic syndrome; Non-alcoholic fatty liver disease; LIPID-ACCUMULATION; MOUSE MODEL; ER STRESS; INFLAMMATION; APOPTOSIS; ACTIVATION; FIBROSIS; PATHWAY; CANCER; STEATOHEPATITIS;
D O I：
10.4196/kjpp.2023.27.4.299
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Non-alcoholic fatty liver disease (NAFLD) is a complex disorder characterized by the accumulation of fat in the liver in the absence of excessive alcohol consumption. It is one of the most common liver diseases worldwide, affecting approximately 25% of the global population. It is closely associated with obesity, type 2 diabetes, and metabolic syndrome. Moreover, NAFLD can progress to non-alcoholic steatohepatitis, which can cause liver cirrhosis, liver failure, and hepatocellular carcinoma. Currently, there are no approved drugs for the treatment of NAFLD. Therefore, the development of effective drugs is essential for NAFLD treatment. In this article, we discuss the experimental models and novel therapeutic targets for NAFLD. Additionally, we propose new strategies for the development of drugs for NAFLD.
引用
收藏
页码：299 / 310
页数：12
相关论文
共 50 条
  • [11] The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)
    Li, Shu-Jing
    Liu, An-Bu
    Yu, Yuan-Yuan
    Ma, Jin-Hai
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [12] Non-alcoholic fatty liver disease: Current therapeutic options
    Majumdar, Avik
    Verbeek, Jef
    Tsochatzis, Emmanuel A.
    CURRENT OPINION IN PHARMACOLOGY, 2021, 61 : 98 - 105
  • [13] Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets
    Ding, Ya-Hui
    Ma, Yuan
    Qian, Lin-Yan
    Xu, Qiang
    Wang, Li-Hong
    Huang, Dong-Sheng
    Zou, Hai
    ONCOTARGET, 2017, 8 (36) : 60673 - 60683
  • [14] VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Tanwar, S.
    Trembling, P.
    Guha, I. N.
    Parkes, J.
    Kaye, P.
    Burt, A. D.
    Ryder, S. D.
    Aithal, G. P.
    Day, C. P.
    Rosenberg, W. M.
    GUT, 2011, 60 : A4 - A5
  • [15] VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Tanwar, Sudeep
    Trembling, Paul M.
    Guha, Indra Neil
    Parkes, Julie
    Kaye, Philip
    Burt, Alastair D.
    Ryder, Stephen D.
    Aithal, Guruprasad P.
    Day, Christopher P.
    Rosenberg, William M.
    HEPATOLOGY, 2011, 54 : 1123A - 1123A
  • [16] An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Marin, Veronica
    Rosso, Natalia
    Dal Ben, Matteo
    Raseni, Alan
    Boschelle, Manuela
    Degrassi, Cristina
    Nemeckova, Ivana
    Nachtigal, Petr
    Avellini, Claudio
    Tiribelli, Claudio
    Gazzin, Silvia
    PLOS ONE, 2016, 11 (07):
  • [17] Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease
    Yu, Qinwei
    Jiang, Zhenzhou
    Zhang, Luyong
    PHARMACOLOGY & THERAPEUTICS, 2018, 190 : 81 - 90
  • [18] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
  • [19] Non-alcoholic fatty liver disease
    Angulo, P
    Lindor, KD
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 : S186 - S190
  • [20] Non-alcoholic fatty liver disease
    Powell, Elizabeth E.
    Wong, Vincent Wai-Sun
    Rinella, Mary
    LANCET, 2021, 397 (10290): : 2212 - 2224
12345